TRAX

NASDAQ Healthcare

First Tracks Biotherapeutics, Inc. - Ordinary Shares

Biotechnology

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.

�� 市场数据
价格$36.21
成交量692,088
市值1.26B
RSI（14日）85.6 超买
50日均线$19.75
52周最高$38.49
52周最低$14.72
Forward P/E-11.17
Price / Book4.91
在Yahoo Finance查看 →
🎯 投资策略评分

TRAX 在各投资策略中的评分。分数越高，越符合该策略目标。

💰 Dividend Daddy 30/100
高股息率 + 低波动性
🔪 Falling Knife 15/100
逆向投资（超卖 + 低于移动均线）
🎈 Over-Hyped 98/100
超买股票（潜在做空标的）
🐋 Institutional Whale 28/100
大盘、机构级别股票
🔍 策略解读

最佳匹配： 🎈 Over-Hyped (98/100) — 此策略 超买股票（潜在做空标的）.

评分最低的策略： 🔪 Falling Knife (15/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →

📚 了解更多
本页指标
教育文章
网站资源
在文本中查找 TRAX in your text

粘贴任何文章、记录或帖子 — 工具将提取 TRAX 以及每一个其他隐藏的股票代码。

试试股票代码提取器 →

免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.